Intellia Therapeutics (NTLA) EBITDA Margin Growth (5y) (2020 - 2026)
Intellia Therapeutics (NTLA) EBITDA Margin Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,225.00 |
| Dec 31, 2025 | 21,404.00 |
| Sep 30, 2025 | -68,239.00 |
| Jun 30, 2025 | -56,905.00 |
| Mar 31, 2025 | -47,070.00 |
| Dec 31, 2024 | -78,764.00 |
| Sep 30, 2024 | -135,038.00 |
| Jun 30, 2024 | -175,162.00 |
| Mar 31, 2024 | -16,579.00 |
| Dec 31, 2023 | 756,072.00 |
| Sep 30, 2023 | -76,798.00 |
| Jun 30, 2023 | -66,613.00 |
| Mar 31, 2023 | -58,782.00 |
| Dec 31, 2022 | -44,042.00 |
| Sep 30, 2022 | -57,853.00 |
| Jun 30, 2022 | -42,995.00 |
| Mar 31, 2022 | -107,362.00 |
| Dec 31, 2021 | -43,328.00 |
| Sep 30, 2021 | -84,127.00 |
| Jun 30, 2021 | -88,855.00 |